PATENT CLAIM ANALYSIS

Application Number: 15869630
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["435", "325000"]

Abstract:
The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates.

Claim (Index 30):
A method of preventing or limiting severity of an adverse event associated with treatment of cancer with intravenously administered coenzyme Q10, comprising administering to a subject having cancer a composition comprising coenzyme Q10 by continuous intravenous infusion for at least 48 hours, wherein the severity of the adverse event in the subject is reduced as compared to intravenous administration of the same dose of coenzyme Q10 over a period of 6 hours or less.

Metadata:
- Claim Count in Document: 188.0
- Percentile: 86.0
- Lexical Diversity: 1.6
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14477828', '11434154', '15376243', '14867554', '12467214']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5682753605449745
- 35 USC 102 Novelty (BERT): 0.663370290140453
- Combined Prediction Score: 0.5777848535045224
- Mean Citation Score: 365.43693
- Max Citation Score: 703.2847
- Similarity Product: 610.0427658263087

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test